Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer

Abstract

Long non-coding small nucleolar RNA host gene 7 (lncRNA SNHG7) is located on chromosome 9q34.3 in length of 984 bp. SNHG7 has been found to play the role of oncogene in varieties of cancers, and its dysregulation has been found to be associated with carcinogenesis and progression. In the present study, we examined the expression of SNHG7 in prostate cancer tissues and in paired adjacent normal prostate tissues, and we further explored the clinical significance and prognostic value of SNHG7 in prostate cancer patients. A total of 127 prostate cancer tissues were collected from prostate cancer patients who underwent radical prostatectomy between April 2011 and March 2019 at the department of urology, Pudong New Area People's Hospital. Real-time quantitative polymerase chain reaction experiment was performed to detect the relative expressions of SNHG7 in the prostate cancer tissues and normal prostate tissues. The Kaplan–Meier method was used to create survival curves and the log-rank test was used to determine statistical significance. A Cox proportional hazard analysis was used to evaluate the prognostic factors in univariate and multivariate analyses. Compared with paired adjacent normal prostatic tissues, SNHG7 expression was increased in prostate cancer tissues (P < .001). Increased SNHG7 expression correlated with Gleason score (P = .021), bone metastasis (P = .013), pelvic lymph node metastasis (P = .008), and TNM stage (P = .007). Multivariate Cox regression analyses revealed increased SNHG7 expression was independently associated with a poor prognosis of prostate cancer patients (hazard ratio [HR] = 2.839, 95% confidence interval [CI] = 1.921–8.382, P = .038). This study showed that lncRNA-SNHG7 was overexpressed in prostate cancer tissues, and it might contributes to the development and progression of prostate cancer. Furthermore, the SNHG7 expression was associated with the prognosis of prostate cancer, suggesting a potential target for the treatment and prognosis of prostate cancer. Nevertheless, the underlying modulatory mechanism by which SNHG7 aggravates prostate cancer progression need to be further studied.

Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis

“…Table 1 summarized the main characteristics of the enrolled twenty-three eligible articles [ 6 , 10 , 18 , 20 , 21 , 24 , 25 , 35 – 50 ]. All of the 2418 participants were from China and divided into high or low group according to the qRT-PCR or microarray results.…”

Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers

“…In particular, SNHG7 reduced the miR-324-3p level, which negatively regulates the Cyclin D1 protein (34). Furthermore, SNHG7 might be an independent risk factor that patients with higher SNHG7 levels were more likely to have an unfavourable outcome than those with lower SNHG7 levels (35).…”

<p>Long Non-Coding Small Nucleolar RNA Host Genes (SNHGs) in Endocrine-Related Cancers</p>

“…142 SNHG7 is also significantly upregulated in prostate cancer tissue and cell lines, 143,144 and correlates with the Gleason score, bone metastasis, pelvic LNM, TNM stage, and OS. 145 In terms of its mechanism of action, SNHG7 knockdown was found to inhibit proliferation and promote CCND1-induced cell cycle arrest at the G0/G1 phase. 144 SNHG7 can also promote EMT via regulating miR-324-3p and WNT2B, an important protein in the Wnt signaling pathway.…”